The content on this site is intended for healthcare professionals only
Dr Benoit Tessoulin speaks to ecancer about a subgroup analysis from the phase 3 EPCORE FL-1 trial evaluating epcoritamab in combination with rituximab and lenalidomide for patients with relapsed or refractory follicular lymphoma.
He reports that the combination consistently improved overall response rates, complete response rates, and progression-free survival compared with rituximab and lenalidomide alone across a range of clinically relevant patient subgroups.
Dr Tessoulin explains that benefits were observed regardless of baseline risk factors, including FLIPI score, POD24 status, comorbidity burden, and lenalidomide dose intensity. Improved outcomes were seen in both higher-risk and lower-risk populations.
Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL
